James Investment Research Inc. Sells 496 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

James Investment Research Inc. reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,579 shares of the biopharmaceutical company’s stock after selling 496 shares during the quarter. James Investment Research Inc.’s holdings in Halozyme Therapeutics were worth $1,366,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after acquiring an additional 30,901 shares in the last quarter. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Boston Trust Walden Corp raised its holdings in shares of Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock valued at $41,790,000 after acquiring an additional 191,465 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Halozyme Therapeutics by 6.2% in the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after acquiring an additional 31,871 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in shares of Halozyme Therapeutics by 28.9% in the third quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock valued at $27,883,000 after acquiring an additional 109,283 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $58.29 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $35.23 and a fifty-two week high of $65.53. The firm has a market capitalization of $7.42 billion, a price-to-earnings ratio of 19.30, a PEG ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock’s 50-day simple moving average is $52.50 and its 200-day simple moving average is $54.49.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Finally, JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.